Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model

November 21, 2017, University of Tampere

Scientists at the University of Tampere (Finland) and the Karolinska Institutet (Sweden) have demonstrated that an enterovirus vaccine can protect against virus-induced diabetes in a mouse model for type 1 diabetes.

Type 1 diabetes is rising worldwide, and to date, the exact causes of the are not known. Enteroviruses (the most common virus affecting humans) are an environmental factor touted as a potential cause of the disease. However, no firm evidence exists proving their role. In this study, Stone et al. have taken an initial step to determine the involvement of these viruses through testing the efficacy of a novel prototype vaccine in preventing experimental type 1 diabetes after enterovirus infection. Vaccination of at risk-individuals with such a vaccine and the subsequent monitoring of disease onset could reveal a role for these viruses in type 1 diabetes. Furthermore, if enteroviruses were involved, vaccination with an enterovirus vaccine would provide a viable preventative treatment for virus-induced type 1 diabetes.

Type 1 diabetes is the most common, chronic, life-threatening disease in children. Finland and Sweden have the highest incidence of type 1 diabetes in the world with more than one in 200 suffering from the disease in Sweden. The disease is caused by the destruction of the cells in the pancreas that produce insulin, the hormone responsible for regulating blood sugar levels. There are currently no preventative treatments and this disease requires life-long insulin injections for survival. Type 1 diabetes is also associated with severe and life-shortening complications including cardiovascular disease, loss of eyesight and a risk of lower limb amputations, and as such, it puts a heavy burden on both the affected individual and the health care system at large.

Currently, there are no commercially available vaccines available for human use that target the enteroviruses that are associated with type 1 diabetes in humans. For the first time, this study by Stone et al. reports that the vaccine prevents diabetes induced by enteroviruses in a clinically relevant model for type 1 diabetes. Furthermore, it also protected against other signs of infection that were seen in control animals and it had no adverse effects on vaccinated animals.

"These exciting results showing that the vaccine completely protects against virus-induced diabetes indicate the potential that such a vaccine has for elucidating the role of enteroviruses in human type 1 diabetes" says Prof. Malin Flodström-Tullberg at the Karolinska Institutet whose group were responsible for the pre-clinical studies.

The researchers are keen to continue pursuing these studies as confirmed by Dr Vesa Hytönen, who produced the prototype vaccine: "The model described in this paper provides an excellent platform to test further enterovirus vaccines containing a greater number of potential diabetogenic viruses. Through these proof-of-concept studies, we hope to develop and experimentally validate an enterovirus vaccine similar to the commonly used poliovirus vaccine, which has the potential to establish whether enteroviruses play a role in type 1 diabetes."

Work is currently ongoing at the University of Tampere to develop a vaccine that targets a greater number of viruses than the single vaccine described in this study, and all of the proposed viruses have been implicated in type 1 . This experimental model provides an exciting opportunity for further proof-of-concept studies before progress to a clinical set-up in humans.

"The experiments here are important steps towards the clinical use of novel enterovirus vaccines. Such a is under further development by Vactech Ltd. and its collaborator Provention Bio for testing in a clinical setting," says professor Heikki Hyöty, University of Tampere, an author in this study and one of the pioneers in this research field.

Explore further: New evidence for the role of a specific virus causing type 1 diabetes

More information: Virginia M. Stone et al, A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes, Diabetologia (2017). DOI: 10.1007/s00125-017-4492-z

Related Stories

New evidence for the role of a specific virus causing type 1 diabetes

October 22, 2013
Type 1 diabetes is a disease caused by the destruction of the insulin-producing cells in the pancreas. It is often diagnosed in childhood and requires life-long treatment with daily insulin injections. It is associated with ...

Study suggests enterovirus infections linked with autoimmunity that leads to type 1 diabetes

January 9, 2017
New research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) shows that children with type 1 diabetes (T1D) have a higher incidence of enterovirus infections prior to experiencing ...

The risk of type 1 diabetes not increased by swine flu vaccine Pandemrix

October 9, 2017
There has been a fear that the swine flu vaccine, Pandemrix, would increase the risk of autoimmune diseases other than narcolepsy. However, a new study of children from Sweden and Finland shows that the vaccine increased ...

Detection of enterovirus infection in pancreatic islets in patients newly diagnosed with type 1 diabetes

December 16, 2014
Norwegian scientists with European partners have found evidence for the presence of enterovirus in pancreatic islets of type 1 diabetic patients. This provides evidence consistent with the theory that a low grade enteroviral ...

Enterovirus infection linked to incidence of T1DM in children

October 20, 2014
(HealthDay)—The risk of type 1 diabetes is increased for children diagnosed with enterovirus infection, according to a study published online Oct. 17 in Diabetologia.

Recommended for you

Switching to certain antidiabetic drugs linked to increased risk of major complications

July 18, 2018
For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.

Researchers cure type 2 diabetes and obesity in mice using gene therapy

July 10, 2018
A research team from the UAB led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy.

Human clinical trial reveals verapamil as an effective type 1 diabetes therapy

July 9, 2018
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent ...

New targets found to reduce blood vessel damage in diabetes

July 9, 2018
In diabetes, both the tightly woven endothelial cells that line our blood vessels and the powerhouses that drive those cells start to come apart as early steps in the destruction of our vasculature.

Insurance gaps linked to five-fold rise in hospital stays for adults with type 1 diabetes

July 9, 2018
For a million American adults, living with type 1 diabetes means a constant need for insulin medication, blood sugar testing supplies and specialized care, to keep them healthy and prevent a crisis that could end up in an ...

Abnormal branched-chain amino acid breakdown may raise diabetes risk

July 5, 2018
In the U.S., about five out of 100 expectant mothers develop gestational diabetes mellitus (GDM), a temporary form of diabetes in which hormonal changes disrupt insulin function. Although GDM is often symptomless and subsides ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.